ReMATCH
The aim of this study is to evaluate the safety and effectiveness of repeat catheter ablation using pulsed field ablation technology in people with persistent atrial fibrillation who have had a previous ablation but continue to experience arrhythmias
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
This study is investigating the safety and effectiveness of two medical devices, called FARAWAVE™ and FARAPOINT™, when used together to treat persistent atrial fibrillation. The study is for people who have previously had a catheter ablation for atrial fibrillation, but whose abnormal heart rhythm has returned and continues to cause symptoms.
Participants in this study require a repeat ablation procedure to help restore or maintain a normal heart rhythm. During the procedure, doctors will use a pulsed field ablation system, which delivers controlled electrical energy to target and treat areas of heart tissue responsible for the abnormal rhythm.
The FARAPULSE™ Pulsed Field Ablation System is considered investigational for this specific use, meaning it is still being studied to better understand how well it works and how safe it is in repeat ablation procedures. The results of this study may help improve future treatment options for people with persistent atrial fibrillation.
Trial Registration Information – https://clinicaltrials.gov/study/NCT06735534
Eligibility
Self screening is not recommended for this study. Eligibility will be confirmed by the study doctor based on medical history and clinical assessment.
Lead investigator
- Dr Tomos Walters
Clinical trial coordinator
- Linda Pearce
Technical title
Repeat Ablation of Persistent Atrial Fibrillation, including Mitral Isthmus and Cavo-Tricuspid Isthmus Ablations, with the FARAPULSE Pulsed Field Ablation System